Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma.

Malouf GG, Duclos J, Rey A, Duvillard P, Lazar V, Haie-Meder C, Balleyguier C, Morice P, Lhommé C, Pautier P.

Ann Oncol. 2010 Oct;21(10):2102-6. doi: 10.1093/annonc/mdq064. Epub 2010 Mar 19.

PMID:
20305035
2.

Stages I to II WHO 2003-defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough?

Feng W, Hua K, Malpica A, Zhou X, Baak JP.

Int J Gynecol Cancer. 2013 Mar;23(3):488-93. doi: 10.1097/IGC.0b013e318247aa14.

PMID:
23435438
3.

Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.

Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K.

Gynecol Oncol. 2001 May;81(2):160-5.

PMID:
11330943
4.

Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer.

Gadducci A, Cosio S, Fabrini MG, Guerrieri ME, Greco C, Genazzani AR.

Anticancer Res. 2012 Jan;32(1):201-5.

PMID:
22213308
5.

Prognostic factors, treatment and outcome in a Turkish population with endometrial stromal sarcoma.

Donertas A, Nayki U, Nayki C, Ulug P, Gultekin E, Yildirim Y.

Asian Pac J Cancer Prev. 2015;16(3):881-7.

6.

Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.

Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53.

PMID:
11483323
7.

[Treatment and prognosis of low-grade malignant endometrial stromal sarcoma].

Ma SK, Zhang HT, Wu LY, Liu LY, Li B.

Zhonghua Zhong Liu Za Zhi. 2007 Jan;29(1):74-8. Chinese.

PMID:
17575701
8.

Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.

Kuku S, Williams M, McCormack M.

Int J Gynecol Cancer. 2013 Jul;23(6):1056-64. doi: 10.1097/IGC.0b013e3182978328.

PMID:
23765205
9.

Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma.

Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, Vergote I, Van Huffel S, Moerman P.

Br J Cancer. 2007 Nov 5;97(9):1194-9. Epub 2007 Sep 25.

10.

Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.

Murphy KT, Rotmensch J, Yamada SD, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. Review.

PMID:
12654437
11.

Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.

Sueoka K, Umayahara K, Abe A, Usami T, Yamamoto A, Nomura H, Matoda M, Okamoto S, Omatsu K, Kondo E, Kato K, Takeshima N.

Int J Gynecol Cancer. 2015 Jan;25(1):81-6. doi: 10.1097/IGC.0000000000000268.

PMID:
25347094
12.

Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran.

Ghaemmaghami F, Karimi-Zarchi M, Gilani MM, Mousavi A, Behtash N, Ghasemi M.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):421-6.

13.

An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.

Liang LW, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Abu-Rustum N, Alektiar KM, Makker V.

Int J Gynecol Cancer. 2016 Mar;26(3):497-504. doi: 10.1097/IGC.0000000000000635.

14.

The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.

Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A, Rubin S, Chu C, Bhatia S, Elshaikh MA, Lin LL.

Int J Gynecol Cancer. 2016 Jan;26(1):141-8. doi: 10.1097/IGC.0000000000000561.

PMID:
26509850
15.

Surgery and adjuvant radiation therapy of endometrial stromal sarcoma.

Weitmann HD, Kucera H, Knocke TH, Pötter R.

Wien Klin Wochenschr. 2002 Jan 15;114(1-2):44-9.

PMID:
12407935
16.

Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages.

Tanz R, Mahfoud T, Bazine A, Aassab R, Benjaafar N, El Khalil El Gueddari B, Ichou M, Errihani H.

Hematol Oncol Stem Cell Ther. 2012;5(1):31-5. doi: 10.5144/1658-3876.2012.31.

17.

[Clinical review of 97 patients with endometrial stromal sarcoma].

Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK.

Zhonghua Fu Chan Ke Za Zhi. 2008 Feb;43(2):115-9. Chinese.

PMID:
18683750
18.

Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.

Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP.

Gynecol Oncol. 2004 Dec;95(3):632-6.

PMID:
15581975
19.

Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.

Zheng M, Huang L, Liu JH, Xiong Y, Li JD, Huang X, He L, Ren YF, Wang HY.

J Surg Oncol. 2011 Oct;104(5):480-5. doi: 10.1002/jso.21956. Epub 2011 May 2.

PMID:
21538358
20.

Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases.

Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK.

Gynecol Oncol. 2008 Feb;108(2):306-11. Epub 2007 Dec 3.

PMID:
18061249

Supplemental Content

Support Center